We are live on
!
Find out more
SGA
Sector Gamma AS Portfolio holdings
AUM
$423M
1-Year Est. Return
17.56%
This Fund
S&P 500
This Quarter
Est. Return
+15.82%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$624M
AUM Growth
+$32.5M
(+5.5%)
Cap. Flow
-$51.3M
Cap. Flow
% of AUM
-8.21%
Top 10 Holdings %
Top 10 Hldgs %
57.01%
Holding
39
New
5
Increased
17
Reduced
15
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$30.5M |
| 2 |
Johnson & Johnson
JNJ
|
+$15.9M |
| 3 |
Biogen
BIIB
|
+$13.8M |
| 4 |
Quest Diagnostics
DGX
|
+$8.03M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$5.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$41.3M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$24.1M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$15.9M |
| 4 |
Eli Lilly
LLY
|
+$15.8M |
| 5 |
Takeda Pharmaceutical
TAK
|
+$15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ultragenyx Pharmaceutical
RARE
$2.81B
| $9.19M | 1.47% |
215,196
+42,218
| +24% | +$1.74M |
|
|
27
Quest Diagnostics
DGX
$23B
| $8.22M | 1.32% |
+76,976
| New | +$8.03M |
|
28
Tenet Healthcare
THC
$16.7B
| $6.5M | 1.04% |
170,896
-258,781
| -60% | -$7.75M |
|
|
29
BioMarin Pharmaceuticals
BMRN
$11.4B
| $6.33M | 1.01% |
+74,903
| New | +$5.66M |
|
|
BLUE
30
DELISTED
bluebird bio
BLUE
| $5.48M | 0.88% |
+4,817
| New | +$5.24M |
|
31
PTC Therapeutics
PTCT
$6.47B
| $4.81M | 0.77% |
100,202
-21,200
| -17% | -$901K |
|
|
CLVS
32
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.26M | 0.68% |
408,625
-22,800
| -5% | -$166K |
|
|
PTLA
33
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.12M | 0.5% |
130,625
+4,700
| +4% | +$130K |
|
34
Agios Pharmaceuticals
AGIO
$2.38B
| $3.05M | 0.49% |
63,913
-39,000
| -38% | -$1.47M |
|
|
35
Eli Lilly
LLY
$1.02T
| $2.04M | 0.33% |
15,524
-136,581
| -90% | -$15.8M |
|
|
SGMO
36
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1.77M | 0.28% |
211,698
-40,000
| -16% | -$368K |
|
|
37
Takeda Pharmaceutical
TAK
$54.4B
| $609K | 0.1% |
30,873
-785,426
| -96% | -$15M |
|
38
Alnylam Pharmaceuticals
ALNY
$36.4B
| – | – |
-96,900
| Closed | -$7.79M |
|
|
39
Baxter International
BAX
$11.4B
| – | – |
-472,305
| Closed | -$41.3M |
|
Similar funds
AFWM
MP
DS
RS
DF
OGM
CPIM
MPPLM
Sector Gamma AS's Q4 2019 Portfolio in Review
As of Q4 2019, Sector Gamma AS held 39 positions worth $624M, up 5.5% from $592M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Sector Gamma AS withdrew a net $51.3M in Q4 2019, closing 2 positions and reducing 15 holdings. Its most notable exit was Baxter International, an estimated $41.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.
Against the trend, Sector Gamma AS opened a new position in Merck worth $32.3M.
- Sector Gamma AS's largest Q4 2019 buy was Merck: 371,825 shares worth $32.3M.
- Sector Gamma AS added most to Biogen in Q4 2019, an estimated $13.8M increase.
- Sector Gamma AS's biggest Q4 2019 reduction was Bristol-Myers Squibb, cutting an estimated $24.1M.
- Sector Gamma AS fully exited Baxter International in Q4 2019, selling an estimated $41.3M.
- Sector Gamma AS's ten largest holdings make up 57% of its $624M portfolio in Q4 2019.
- Sector Gamma AS opened 5 new positions and closed 2 in Q4 2019.
- Sector Gamma AS's portfolio value rose 5.5% quarter-over-quarter to $624M.
Based on Sector Gamma AS's 13F filing for Q4 2019, filed 12 Feb 2020.